Under the Radar: Liquidia Stock Soars After Settling Patent Fight

Dow Jones10-14

Shares of Liquidia surged nearly 30% this morning after the company settled six lawsuits with rival United Therapeutics, ending multiyear litigation that had threatened to restrict sales of Liquidia's main drug, called Yutrepia.

Morrisville, N.C.-based Liquidia said it will pay around $380 million to United Therapeutics through 2027. Yutrepia, an inhaled lung drug, will stay on the market for pulmonary arterial hypertension, a disease that narrows the arteries in the lungs.

In September, a judge found Liquidia infringed a United Therapeutics patent covering the use of the active ingredient in Yutrepia to treat patients with a different lung disease. Liquidia shares fell 57% that day. As part of its settlement, Liquidia agreed not to appeal and said it will stop promoting Yutrepia for that condition.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment